Sign up Australia
Proactive Investors - Run By Investors For Investors

VolitionRx surges after unveiling plans to conduct two massive clinical studies

The cancer test specialist has signed a memorandum of understanding (MoU) with the National Taiwan University.
Cancer newspaper story
"We continue to announce large trials at very affordable costs in our efforts to gain worldwide adoption of our products."

VolitionRx Ltd's (NYSEAMERICAN:VNRX) stock shot up after it signed a memorandum of understanding with the National Taiwan University to conduct two large clinical studies.

The studies will entail taking some 7,000 patient samples.

"The signing of this MOU is a good start for Volition in the Asia Pacific Region" said Dr Jasmine Kway, Volition's vice president of Asia. 

"We are fortunate and delighted to be working with a renowned institution and Professor Han-Mo Chiu, a prominent thought leader. This large-scale study will be low cost in line with Volition's other great value studies such as the 13,500-subject study in the US and the ongoing 30,000-subject prospective study in Europe and demonstrates our commitment to conducting large trials worldwide to drive the acceptance of our products," Dr Kway added.

VolitionRx said the first trial would be a large scale multi-country, multi-center and multi-ethnic study in the Asia Pacific region, including 5,000 asymptomatic colorectal cancer screening subjects.

The second trial will include up to 2,000 symptomatic colorectal cancer patients.

These studies are being conducted to test and validate Volition's proprietary Nu.Q platform for the detection and diagnosis of colorectal cancer for marketing, rather than for regulatory purposes.

In a separate announcement, the company released its third quarter results in which it listed a slew of achievements and some upcoming milestones.

The latter include the selection of the panel for the company's front-line Nu.Q Colorectal Cancer Screening Test by the end of this year.

Also on its to-do list is the completion of the Logistics and Pathway design study that is currently in progress in Denmark, and the publication of an update on its progress using nucleosomics to purify or enrich nucleosomes of tumor origin.

"We have made fantastic progress this quarter, moving our clinical product development strongly forward in Asia, Europe and the US, and broadening our potential revenue base with our recently announced research kit sales,” said Cameron Reynolds, president and chief executive of VolitionRx.

READ VolitionRx lifted by cash infusion and first order for new range of "research use only" kits

“We have further expanded our talented scientific team, with four new hires to the R&D team, financially supported by the local government in Belgium." Reynolds added.

"We continue to announce large trials at very affordable costs in our efforts to gain worldwide adoption of our products. We look forward to achieving our upcoming clinical and commercial milestones, while continuing to keep close control on our cash burn, which has remained relatively stable," he concluded.

Cash and cash equivalents at the end of September stood US$13.84 million, compared with US$12.53mln a year earlier.

The company posted a net loss of US$3.89mln, equivalent to 15 cents a share, versus a loss the year before of US$3.48mln (15 cents a share).

Shares in VolitionRx rose to US$3.72 in the morning trading session from US$3.12 overnight.



John-H.jpg
Why Invest In VolitionRx? Read More Here

Register here to be notified of future VNRX Company articles
View full VNRX profile View Profile

VolitionRx Timeline

Newswire
September 15 2017

Related Articles

test tubes filled with blood
November 03 2017
In all, 116 of the 200 patients with the life-threatening auto-immune disease have been through the 52-week process looking at the efficacy of Lupuzor
Clinical Trial
August 04 2017
The study, codenamed INTEREST, should be wrapped up in the fourth-quarter
biotechLatest.jpg
March 28 2017
2017 is going to be quite action packed we believe we have positioned the company for when RNA interference transforms from a technology to its promise of a new class of therapeutics - boss Ali Mortazavi.

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use